This is analogous with other case reports that have noted a worsening of the disease in patients with AQP4 + NMOSD receiving DMTs classically used to treat MS such as beta-interferons, fingolimod, and in particular natalizumab, with accumulation of disability and disease progression [14–16]. This evidence concerns the gene IFNB1 and myeloid sarcoma.